
|Articles|November 16, 2012
Direct renin inhibitor adjunct not helpful in T2DM patients at high risk for CV, renal events
Adding aliskiren to standard therapy with renin-angiotensin system blockade could be harmful and did not lower the risk of cardiovascular and renal adverse events when used in patients with type 2 diabetes at risk for these events, according to an online study in the New England Journal of Medicine.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
Ixekizumab, Tirzepatide Maintains Efficacy in Psoriatic Disease
4
Measles Resurgence Exposes US Vaccine Policy Risks, Experts Warn
5






































